Cost–Utility Analysis of Tenofovir Alafenamide and Entecavir in Chronic Hepatitis B Patients: A Markov Decision Model

Cost–Utility Analysis of Tenofovir Alafenamide and Entecavir in Chronic Hepatitis B Patients: A Markov Decision Model

From the perspective of health economics, the evaluation of drug-related cost effectiveness and clinical utility is crucial. We conducted a cost–utility analysis of two first-line drugs, tenofovir alafenamide (TAF) and entecavir (ETV), in the treatment of chronic hepatitis B (CHB) patients. We perfo...

Full description

Bibliographic Details
Main Authors: Chun-Huang Lai, Hon-Yi Shi, Cheng-En Tsai, Yuan-Chieh Yang, Si-Un Frank Chiu
Format: Article
Language:English
Published: MDPI AG 2024-02-01
Series:Cancers
Subjects:
chronic hepatitis B
tenofovir alafenamide
entecavir
inverse probability of treatment weighting
cost–utility analysis
Online Access:https://www.mdpi.com/2072-6694/16/4/813

Similar Items

Similar Items